The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The protections extend through at least 2035, with the potential for further extensions
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
_256_384.jpg)
Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025
Laurus Labs has reported total income of Rs. 1,784.05 crore during the period ended December 31, 2025
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated
